Markets

Baron Funds Comments on Bristol-Myers Squibb Company

After initiating a position in Bristol-Myers Squibb Company ( BMY ), we increased our conviction in BMY's stature as one of the premier names in all of biotech/pharma, deserving of its high multiple. Confidence comes from the performance of its lead immune-oncology asset, Opdivo that has captured 8…-85% market share versus Merck's competitive asset Keytruda, while growing -…--…% month over month. Given the frenetic pace of growth, we expect Opdivo to easily beat -…-6's $-.- billion Consensus sales number. Looking past -…-6, we expect this trend to continue as Bristol launches and/or expands usage of Opdivo in a variety of cancers (lung, melanoma, renal, head and neck, hodgkin's lymphoma, etc.) and helps change the paradigm of cancer's treatment worldwide.

LNC 15-Year Financial Data

The intrinsic value of LNC

Peter Lynch Chart of LNC

Warning! GuruFocus has detected 1 Warning Sign with AL. Click here to check it out.

AL 15-Year Financial Data

The intrinsic value of AL

Peter Lynch Chart of AL

Warning! GuruFocus has detected 6 Warning Sign with IRM. Click here to check it out.

IRM 15-Year Financial Data

The intrinsic value of IRM

Peter Lynch Chart of IRM

Warning! GuruFocus has detected 6 Warning Sign with IRM. Click here to check it out.

SCOR 15-Year Financial Data

The intrinsic value of SCOR

Peter Lynch Chart of SCOR

Warning! GuruFocus has detected 7 Warning Signs with BMY. Click here to check it out.

BMY 15-Year Financial Data

The intrinsic value of BMY

Peter Lynch Chart of BMY

From Baron Opportunity Fund first quarter -…-6 commentary .

Read More:

About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BMY

Other Topics

Stocks